Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121


Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.

Koshkina NV, Briggs K, Palalon F, Curley SA.

Cancer. 2014 Feb 15;120(4):480-91. doi: 10.1002/cncr.28453. Epub 2013 Oct 25.


Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.

Glazer ES, Zhu C, Massey KL, Thompson CS, Kaluarachchi WD, Hamir AN, Curley SA.

Clin Cancer Res. 2010 Dec 1;16(23):5712-21. doi: 10.1158/1078-0432.CCR-10-2055.


The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation.

Mukubou H, Tsujimura T, Sasaki R, Ku Y.

Int J Oncol. 2010 Oct;37(4):821-8.


Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells.

Curley SA, Palalon F, Lu X, Koshkina NV.

Cancer. 2014 Nov 1;120(21):3418-25. doi: 10.1002/cncr.28895. Epub 2014 Jul 1.


Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.

Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW.

Mol Cancer. 2013 Sep 11;12(1):104. doi: 10.1186/1476-4598-12-104.


Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.

Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M.

Biochim Biophys Acta. 2015 Jan;1853(1):89-100. doi: 10.1016/j.bbamcr.2014.10.003. Epub 2014 Oct 13.


miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.

Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.

Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.


Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.

Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.

J Exp Clin Cancer Res. 2013 Mar 6;32:12. doi: 10.1186/1756-9966-32-12.


Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.

Wang X, McKernan R, Kim KH, Alvero AB, Whiting A, Thompson JA, Mor G, Saif MW, Husband AJ, Brown DM, Tytler EM.

Anticancer Drugs. 2011 Sep;22(8):719-31. doi: 10.1097/CAD.0b013e328346f3b4.


Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.

Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC.

Cancer Res. 2015 Jun 1;75(11):2292-304. doi: 10.1158/0008-5472.CAN-14-2397. Epub 2015 Apr 3.


BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.


Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.

Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ.

Cancer Chemother Pharmacol. 2005 Nov;56(5):510-20. Epub 2005 Jun 10.


Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.

Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R.

Clin Cancer Res. 2006 Dec 1;12(23):7099-107.


Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH.

Cancer Res. 2005 Oct 1;65(19):9064-72.


The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Awasthi N, Yen PL, Schwarz MA, Schwarz RE.

J Cell Biochem. 2012 Mar;113(3):784-91. doi: 10.1002/jcb.23405.


Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.

Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.

Cancer Lett. 2015 Mar 1;358(1):59-66. doi: 10.1016/j.canlet.2014.12.027. Epub 2014 Dec 16.


Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Biol Ther. 2010 Jul 1;10(1):99-107. Epub 2010 Jul 26.


Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.

Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M.

Cancer Sci. 2012 Jul;103(7):1272-9. doi: 10.1111/j.1349-7006.2012.02297.x. Epub 2012 May 17.


Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.

Awasthi N, Kirane A, Schwarz MA, Toombs JE, Brekken RA, Schwarz RE.

BMC Cancer. 2011 Jan 12;11:15. doi: 10.1186/1471-2407-11-15.


EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.

Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA.

Ann Surg Oncol. 2010 May;17(5):1442-52. doi: 10.1245/s10434-009-0879-5. Epub 2009 Dec 30.

Items per page

Supplemental Content

Write to the Help Desk